Talk:Labetalol

Wiki Education Foundation-supported course assignment
This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): Sophien21, PharmIsPhun21, Toastntea21, JBarHP21. Peer reviewers: Elainelin20, Tgu20, RobP20, Ally-oop20.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 02:04, 17 January 2022 (UTC)

Chemistry Section
Hey I'm a moron but also have a PhD and think this could be written more clearly and worded more carefully eh?

99.194.148.25 (talk) 21:21, 21 April 2011 (UTC)

Please clarify

 * Please explain what does 3:1 Beta:alpha antagonistic activity mean? Because if effect on peripheral vascular resistance is more pronounced than that on the heart then shouldn't it be 1:3? May be i have understood it wrong. Please clarify asap.Ashu 17:04, 11 February 2012 (UTC) — Preceding unsigned comment added by Ashu1990 (talk • contribs)

UCSF Health Policy Elective 2015
The overall goals of this edit were to further expand on each section while providing adequate references for each concept.

1. Lead I look at the lead as a brief summary of the take-away points of the article. Because the lead was one sentence long, I felt that adding content from the main article sections would provide readers with an overview of what is to come.

2. Medical uses I wanted to include a special population section that would provide safety information about pregnant women, nursing women, children and the elderly.

3. Side effects When I look at side effects, I want to know how prevalent they are, what to look out for, and which side effects are rare and dangerous. For that reason, I wanted to separate the side effects into common/rare and provide percentages for prevalence

4. Chemistry The chemistry section was commented back in April 2011 for being confusing. I wanted to further expand on the structure activity relationship, and the structural features of labetalol.

5. Mechanism of Action The mechanism of action is the core of this drug -- how it works, why it works, what it does in short and long term situations. Because this section had information copied/pasted from the package insert and a couple of papers, the goal of this edit was to paraphrase, properly cite, and add in the desired information. I hope that the additional information further clarified labetalol's oddities in that it does not have the exact predicted effects by antagonizing the receptors. I thought expanding on the short and long term effects helped demonstrate why solely thinking about the effects of each receptor does not work for labetalol.

6. History I believe that knowing why a certain drug was created helps emphasize the creativity of researchers, and the need for differing drug types. Because there was no history, I felt that adding one would give readers context as to why dual alpha/beta receptor antagonists exist. — Preceding unsigned comment added by PharmIsPhun21 (talk • contribs) 09:58, 5 November 2015 (UTC)

UCSF Peer review 11/8/2015
Neutral POV - yes Verifiable Citations – yes

Recommendations: 1. Fixed spelling error in Special Populations 2. We suggest trimming the Geriatric counseling recommendation as this is more appropriate for providers and not general wikipedia users 3. Consider trimming the MOA as it gives more information than the mechanism of action or either dividing it into appropriate sections (it includes pharmacokinetics [BBB crossing], pharmacology, additional properties [anesthetic properties], etc.). in addition, not sure about the relevance of receptor blockade ratio for the context of this article. 4. We weren’t able to validate that labetalol is contraindicated in CHF [overt cardiac failure is C/I, not CHF]. the package insert lists it as an advisory Ally-oop20 (talk) 06:35, 9 November 2015 (UTC)